Study guide

AKI and chronic kidney disease

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

AKI and chronic kidney disease

Key Takeaways Explain This Topic AI

CKD requires persistent kidney abnormalities for at least three months.

G3a CKD has an eGFR of 45–59 mL/min/1.73 m².

FENa has important limitations, including diuretic use and some intrinsic renal disorders.

Last updated: October 2026

Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

Renal parenchymal integrity and fluid-electrolyte equilibrium are essential for systemic haemodynamic stability. Acute deterioration in renal function and severe electrolyte derangements—predominantly hyperkalaemia and dysnatraemias—account for a major proportion of emergency admissions and inpatient medical consultations in Australian hospitals.

Acute Kidney Injury (AKI): Staging & Aetiology

The Kidney Disease: Improving Global Outcomes (KDIGO) criteria standardize the clinical definition and staging of acute kidney injury.

KDIGO Diagnostic Staging of AKI

Stage 1 : Serum Creatinine Criteria: Increase ≥ 26.5 μ mol/L \ge 26.5\ \mu\text{mol/L} ≥ 26.5 μ mol/L within 48 hours, or 1.5 − 1.9 × 1.5 - 1.9 \times 1.5 − 1.9 × baseline within 7 days; Urine Output Criteria: < 0.5 mL/kg/hour < 0.5\text{ mL/kg/hour} < 0.5 mL/kg/hour for 6 to 12 hours

Stage 2 : Serum Creatinine Criteria: 2.0 − 2.9 × 2.0 - 2.9 \times 2.0 − 2.9 × baseline serum creatinine; Urine Output Criteria: < 0.5 mL/kg/hour < 0.5\text{ mL/kg/hour} < 0.5 mL/kg/hour for ≥ 12 \ge 12 ≥ 12 hours

Stage 3 : Serum Creatinine Criteria: ≥ 3.0 × \ge 3.0 \times ≥ 3.0 × baseline, or serum creatinine ≥ 353.6 μ mol/L \ge 353.6\ \mu\text{mol/L} ≥ 353.6 μ mol/L , or initiation of renal replacement therapy; Urine Output Criteria: < 0.3 mL/kg/hour < 0.3\text{ mL/kg/hour} < 0.3 mL/kg/hour for ≥ 24 \ge 24 ≥ 24 hours, or anuria for ≥ 12 \ge 12 ≥ 12 hours

Aetiological Classification of AKI

Prerenal Azotaemia ( 55 − 60 % 55-60\% 55 − 60% ):

Decreased effective arterial blood volume and renal hypoperfusion with preserved parenchymal and tubular architecture.

Common Precipitants: Dehydration, haemorrhage, septic shock, congestive heart failure (cardiorenal syndrome), liver cirrhosis (hepatorenal syndrome).

The 'Triple Whammy' Drug Interaction: The combination of an ACE inhibitor or ARB (blocks angiotensin II-mediated efferent arteriolar vasoconstriction), an NSAID (blocks prostaglandin-mediated afferent arteriolar vasodilation), and a diuretic (induces intravascular hypovolaemia). This trio cripples intraglomerular hydrostatic pressure, precipitating acute prerenal failure.

Intrinsic Renal Injury ( 35 − 40 % 35-40\% 35 − 40% ):

Direct structural damage to glomeruli, tubules, interstitium, or renal microvasculature.

Acute Tubular Necrosis (ATN, 85 % 85\% 85% of intrinsic):

Ischaemic ATN: Prolonged, severe prerenal hypoperfusion leading to tubular epithelial hypoxia and necrosis.

Nephrotoxic ATN: Aminoglycosides (gentamicin), iodinated radiocontrast media, cisplatin, amphotericin B, or endogenous pigments (myoglobin from rhabdomyolysis [elevated serum creatine kinase, dipstick positive for 'blood' with zero RBCs on microscopy], haemoglobin from massive intravascular haemolysis, light chains in multiple myeloma).

Acute Interstitial Nephritis (AIN): Drug-induced allergic hypersensitivity ( > 75 % > 75\% > 75% of cases: penicillins, cephalosporins, sulfonamides, proton pump inhibitors, NSAIDs). Classic clinical triad: low-grade fever, maculopapular rash, and arthralgia/eosinophilia (present in < 30 % < 30\% < 30% ). Urine microscopy shows sterile pyuria, white blood cell casts, and eosinophiluria. Managed by prompt drug cessation ± \pm ± oral corticosteroids.

Acute Glomerulonephritis (Nephritic Syndrome): Immune-complex deposition or ANCA vasculitis; characterized by hypertension, oliguria, dysmorphic red blood cells, and red blood cell casts .

Postrenal / Obstructive Uropathy ( 5 − 10 % 5-10\% 5 − 10% ):

Mechanical blockage of urinary flow from the renal pelvis to the urethral meatus.

Bladder outlet obstruction (benign prostatic hyperplasia, prostate adenocarcinoma, neurogenic bladder, blocked urinary catheter) or bilateral ureteric obstruction.

First-Line Investigation: Urgent renal tract ultrasound to evaluate for hydronephrosis and assess post-void residual bladder volume.

Urinary Indices: Prerenal vs ATN Fractional Excretion of Sodium (FeNa) = Urine Na × Serum Creatinine Serum Na × Urine Creatinine × 100 \text{Fractional Excretion of Sodium (FeNa)} = \frac{\text{Urine Na} \times \text{Serum Creatinine}}{\text{Serum Na} \times \text{Urine Creatinine}} \times 100 Fractional Excretion of Sodium (FeNa) = Serum Na × Urine Creatinine Urine Na × Serum Creatinine ​ × 100

Urine Sodium ( U Na \text{U}_{\text{Na}} U Na ​ ) : Prerenal Azotaemia: < 20 mmol/L < 20\text{ mmol/L} < 20 mmol/L (avidity to conserve sodium); Acute Tubular Necrosis (ATN): > 40 mmol/L > 40\text{ mmol/L} > 40 mmol/L (impaired tubular reabsorption)

Fractional Excretion of Sodium (FeNa) : Prerenal Azotaemia: < 1 % < 1\% < 1% ; Acute Tubular Necrosis (ATN): > 2 % > 2\% > 2%

Fractional Excretion of Urea (FeUrea) : Prerenal Azotaemia: < 35 % < 35\% < 35% (preferred if patient takes loop diuretics); Acute Tubular Necrosis (ATN): > 50 % > 50\% > 50%

Urine Osmolality : Prerenal Azotaemia: > 500 mOsm/kg > 500\text{ mOsm/kg} > 500 mOsm/kg (intact concentrating ability); Acute Tubular Necrosis (ATN): < 350 mOsm/kg < 350\text{ mOsm/kg} < 350 mOsm/kg (isosthenuria)

Urea/creatinine: Interpret each result in its own units and clinical context. Do not apply a ratio of unconverted mmol/L urea and micromol/L creatinine as if dimensionless. Dehydration, GI bleeding, diet and kidney function all affect the pattern.

Urine Sediment Microscopy : Prerenal Azotaemia: Normal or Hyaline casts ; Acute Tubular Necrosis (ATN): 'Muddy brown' granular casts , epithelial cells

Chronic Kidney Disease (CKD) Staging & Complications

Chronic kidney disease is defined by persistent kidney damage or an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m 2 < 60\text{ mL/min/1.73 m}^2 < 60 mL/min/1.73 m 2 present for ≥ 3 months \ge 3\text{ months} ≥ 3 months .

The KDIGO GFR and Albuminuria Matrix

G1 : eGFR ( mL/min/1.73 m 2 \text{mL/min/1.73 m}^2 mL/min/1.73 m 2 ): ≥ 90 \ge 90 ≥ 90 ; Description: Normal or high (with other kidney damage); Albuminuria Stage: A1 ; Urine ACR ( mg/mmol \text{mg/mmol} mg/mmol ): < 3.0 < 3.0 < 3.0 ; Description: Normal to mildly increased

G2 : eGFR ( mL/min/1.73 m 2 \text{mL/min/1.73 m}^2 mL/min/1.73 m 2 ): 60 − 89 60 - 89 60 − 89 ; Description: Mildly decreased; Albuminuria Stage: A2 ; Urine ACR ( mg/mmol \text{mg/mmol} mg/mmol ): 3.0 − 30.0 3.0 - 30.0 3.0 − 30.0 ; Description: Moderately increased (microalbuminuria)

G3a : eGFR ( mL/min/1.73 m 2 \text{mL/min/1.73 m}^2 mL/min/1.73 m 2 ): 45 − 54 45 - 54 45 − 54 ; Description: Mild-to-moderately decreased; Albuminuria Stage: A3 ; Urine ACR ( mg/mmol \text{mg/mmol} mg/mmol ): > 30.0 > 30.0 > 30.0 ; Description: Severely increased (macroalbuminuria)

G3b : eGFR ( mL/min/1.73 m 2 \text{mL/min/1.73 m}^2 mL/min/1.73 m 2 ): 30 − 44 30 - 44 30 − 44 ; Description: Moderately-to-severely decreased; Albuminuria Stage: —; Urine ACR ( mg/mmol \text{mg/mmol} mg/mmol ): —; Description: —

G4 : eGFR ( mL/min/1.73 m 2 \text{mL/min/1.73 m}^2 mL/min/1.73 m 2 ): 15 − 29 15 - 29 15 − 29 ; Description: Severely decreased; Albuminuria Stage: —; Urine ACR ( mg/mmol \text{mg/mmol} mg/mmol ): —; Description: —

G5 : eGFR ( mL/min/1.73 m 2 \text{mL/min/1.73 m}^2 mL/min/1.73 m 2 ): < 15 < 15 < 15 ; Description: Kidney failure (End-stage kidney disease); Albuminuria Stage: —; Urine ACR ( mg/mmol \text{mg/mmol} mg/mmol ): —; Description: —

Complications of Advanced CKD & Management

Anaemia of CKD:

Primarily driven by deficient erythropoietin (EPO) synthesis by renal peritubular interstitial fibroblasts. Normocytic, normochromic anaemia.

CKD anaemia: Check iron status and other correctable causes before choosing treatment. KDIGO 2026 iron criteria vary by dialysis status: do not use one universal ferritin target for every patient. Select oral or intravenous iron according to circumstances and response. ESA initiation considers symptoms, haemoglobin, transfusion risk and adverse effects; when used in adults, keep the haemoglobin target below 115 g/L rather than normalising it. Monitor iron indices, blood pressure and response.

CKD-Mineral and Bone Disorder (CKD-MBD):

CKD mineral/bone disorder: Phosphate retention and reduced active vitamin D contribute to altered calcium/PTH and bone turnover. Interpret serial calcium, phosphate and PTH together. Calciphylaxis is a distinct severe multifactorial disorder, not synonymous with ordinary vascular calcification.

Secondary hyperparathyroidism: Cinacalcet increases calcium-sensing receptor sensitivity, suppressing PTH; it does not inhibit that receptor. In non-dialysis CKD, trends in calcium, phosphate and PTH guide management. Routine calcitriol for every stage 3–5 patient or a normal-laboratory PTH target for stage 4 is inappropriate.

CKD acidosis: KDIGO 2024 advises considering treatment when acidosis has potential clinical consequences, for example bicarbonate below 18 mmol/L. Dose and monitor to avoid hypertension, fluid overload or excessive correction; 22 is not a universal mandatory drug-treatment threshold.

Cardiovascular Risk Reduction: Cardiovascular disease is the single leading cause of death in CKD. Blood pressure targets < 130 / 80 mmHg < 130/80\text{ mmHg} < 130/80 mmHg using an ACE inhibitor or ARB (reduces intraglomerular pressure and proteinuria) plus an SGLT2 inhibitor (empagliflozin/dapagliflozin) for cardiovascular and renal protection.

Primary references (checked 7 October 2026): KDIGO CKD guidance .

KDIGO 2026 anaemia guideline updates iron and ESA decisions.